iShares MSCI China ETF vs Morgan Stanley — how do they compare? iShares MSCI China ETF trades at $52.39 (market cap $5.94B), while Morgan Stanley trades at $187.86 (market cap $294.39B). The key difference: Morgan Stanley is far larger — about 49.6× iShares MSCI China ETF's market cap, and Morgan Stanley pays a 2.45% dividend while iShares MSCI China ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI China ETF for 63 Days and Morgan Stanley for 93 Days on average.
| MCHI | MS | |
|---|---|---|
Market Cap | $5.94B | $294.39B |
Volume | 1,575,471 | 5,836,423 |
Sector | Broad Market / Factor | Financials |
52-Week High | $65.59 | $228.42 |
52-Week Low | $50.48 | $151.86 |
Typical Hold Time | 63 Days | 93 Days |
Enterprise Value | — | $660.04B |
Dividend Yield | — | 2.45% |
Signals from Pluang's Aura AI — not financial advice
MCHI trades at $52.45, up 1.57% with a bearish technical outlook as moving averages signal strong selling pressure. The ETF faces headwinds from China's economic challenges including industrial overcapacity and weak domestic consumption. Recent news highlights mixed signals with corporate profits surging 26% in Q2 2026 while exports face global pushback. Institutional activity shows conflicting positions with Empowered Funds acquiring shares while Acima Private Wealth reduced holdings.
The outlook remains cautious given China's macroeconomic pressures and trade tensions. Investment opportunity exists in the significant discount to historical valuations, but risks include potential export controls, protectionism threats, and ongoing economic rebalancing challenges that could pressure Chinese equities.
Morgan Stanley (MS) trades at $189.71, down 0.66% with bearish technical signals despite strong fundamentals. The company has delivered three consecutive earnings beats with Q2 2026 EPS of $3.46 beating expectations by $0.57. Revenue growth accelerated to $66.0 billion in 2025 with net income margin expanding to 27.59%. Analyst consensus remains bullish with 55.77% buy ratings and a $229.25 price target representing 21% upside potential.
The investment case balances strong profitability and growth opportunities in wealth management and AI financing against concerning cash flow trends and technical weakness. While valuation appears reasonable at 15.14 P/E, investors face risks from volatile operating cash flows and rising debt levels. The stock offers attractive upside to analyst targets but requires monitoring of capital markets recovery timing.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →